Astrazeneca (AZN) Cash & Current Investments (2009 - 2026)

Astrazeneca has reported Cash & Current Investments for 18 years, with the latest figure at $5.3 billion in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 30.13% year-over-year to $5.3 billion in Q2 2026; TTM through Jun 2026 was $5.3 billion, a 30.13% decrease from a year earlier, with the FY2025 full-year figure at $6.2 billion, up 9.51% from the prior year.
• Cash & Current Investments was $5.3 billion for Q2 2026 at Astrazeneca, down from $7.9 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $10.4 billion in Q4 2023, with the low at $4.6 billion in Q3 2022.
• Average Cash & Current Investments over 5 years is $6.4 billion, with a median of $6.0 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 68.58% in 2022, then surged 70.51% in 2023.
• Over 5 years, Cash & Current Investments stood at $6.1 billion in 2022, then soared by 70.51% to $10.4 billion in 2023, then tumbled by 45.24% to $5.7 billion in 2024, then increased by 9.51% to $6.2 billion in 2025, then slipped by 14.85% to $5.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $5.3 billion (Q2 2026), $7.9 billion (Q1 2026), and $6.2 billion (Q4 2025), per Business Quant data.